CALADRIUS BIOSCIENCES INC (CLBS) Stock Price, Quote, News and Overview
NASDAQ:CLBS - Nasdaq - US1280582032 - Common Stock - Currency: USD
CLBS Quote, Performance and Key Statistics
0.4264
-0.08 (-16.44%)
The current stock price of CLBS is 0.4264 USD. In the past month the price decreased by -21.05%. In the past year, price decreased by -64.47%.
CLBS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CLBS
Company Profile
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
Company Info
CALADRIUS BIOSCIENCES INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY 07920 US
CEO: David J. Mazzo
Employees: 27
Company Website: https://www.caladrius.com/
Phone: 19082292590.0
CALADRIUS BIOSCIENCES INC / CLBS FAQ
What is the stock price of CALADRIUS BIOSCIENCES INC today?
The current stock price of CLBS is 0.4264 USD. The price decreased by -16.44% in the last trading session.
What is the ticker symbol for CALADRIUS BIOSCIENCES INC stock?
The exchange symbol of CALADRIUS BIOSCIENCES INC is CLBS and it is listed on the Nasdaq exchange.
On which exchange is CLBS stock listed?
CLBS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CALADRIUS BIOSCIENCES INC stock?
8 analysts have analysed CLBS and the average price target is 4.59 USD. This implies a price increase of 976.45% is expected in the next year compared to the current price of 0.4264. Check the CALADRIUS BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CALADRIUS BIOSCIENCES INC worth?
CALADRIUS BIOSCIENCES INC (CLBS) has a market capitalization of 1.72M USD. This makes CLBS a Nano Cap stock.
How many employees does CALADRIUS BIOSCIENCES INC have?
CALADRIUS BIOSCIENCES INC (CLBS) currently has 27 employees.
What are the support and resistance levels for CALADRIUS BIOSCIENCES INC (CLBS) stock?
CALADRIUS BIOSCIENCES INC (CLBS) has a resistance level at 0.5. Check the full technical report for a detailed analysis of CLBS support and resistance levels.
Should I buy CALADRIUS BIOSCIENCES INC (CLBS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLBS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLBS, evaluating the profitability, health, valuation and growth aspects
- CALADRIUS BIOSCIENCES INC (CLBS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CALADRIUS BIOSCIENCES INC (CLBS) Sales and EPS estimates to see what analysts future expectations are.
- CALADRIUS BIOSCIENCES INC (CLBS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CALADRIUS BIOSCIENCES INC (CLBS) Insider and Institutional Ownership to learn about the owners and their transactions.
- CALADRIUS BIOSCIENCES INC (CLBS) Stock Chart to make your own analysis
- CALADRIUS BIOSCIENCES INC (CLBS) Latest news and press-releases to stay up to date.
Does CALADRIUS BIOSCIENCES INC (CLBS) stock pay dividends?
CLBS does not pay a dividend.
When does CALADRIUS BIOSCIENCES INC (CLBS) report earnings?
CALADRIUS BIOSCIENCES INC (CLBS) will report earnings on 2022-11-02.
What is the Price/Earnings (PE) ratio of CALADRIUS BIOSCIENCES INC (CLBS)?
CALADRIUS BIOSCIENCES INC (CLBS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
CLBS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLBS. When comparing the yearly performance of all stocks, CLBS is a bad performer in the overall market: 84.2% of all stocks are doing better.
CLBS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLBS. CLBS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CLBS Financial Highlights
Over the last trailing twelve months CLBS reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 52.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.61% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CLBS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CLBS. The Buy consensus is the average rating of analysts ratings from 8 analysts.